Asia Pacific Huntingtons Disease Treatment Market Size & Outlook
Related Markets
Asia Pacific huntingtons disease treatment market highlights
- The Asia Pacific huntingtons disease treatment market generated a revenue of USD 136.9 million in 2024.
- The market is expected to grow at a CAGR of 24.4% from 2025 to 2030.
- In terms of segment, symptomatic treatment was the largest revenue generating treatment in 2024.
- Symptomatic Treatment is the most lucrative treatment segment registering the fastest growth during the forecast period.
- Country-wise, Japan is expected to register the highest CAGR from 2025 to 2030.
Asia Pacific data book summary
| Market revenue in 2024 | USD 136.9 million |
| Market revenue in 2030 | USD 525.8 million |
| Growth rate | 24.4% (CAGR from 2025 to 2030) |
| Largest segment | Symptomatic treatment |
| Fastest growing segment | Symptomatic Treatment |
| Historical data covered | 2018 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Symptomatic Treatment |
| Key market players worldwide | H. Lundbeck AS Class A, Teva Pharmaceutical Industries Ltd, Bausch Health Companies Inc, Hetero, Lupin, Hikma Pharmaceuticals PLC, Dr Reddy's Laboratories Ltd ADR, Sun Pharmaceutical Industries |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 27.3% of the global huntingtons disease treatment market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 525.8 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Huntingtons Disease Treatment Market Scope
Huntingtons Disease Treatment Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Asia Pacific huntingtons disease treatment market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to huntingtons disease treatment market will help companies and investors design strategic landscapes.
Symptomatic treatment was the largest segment with a revenue share of 129% in 2024. Horizon Databook has segmented the Asia Pacific huntingtons disease treatment market based on symptomatic treatment covering the revenue growth of each sub-segment from 2018 to 2030.
There is little to no reimbursement in underdeveloped economies. Improving healthcare reimbursement guidelines, presence of larger target population in India & China as compared to other Asian countries, and high unmet needs are among factors expected to provide lucrative growth opportunity to companies in this region.
Rising number of initiatives being undertaken by governments to improve health status of the population is expected to drive market growth during the forecast period. However, the market is competitive, which may hamper market growth in this region.
For instance, in July 2021, Teva Pharmaceutical Industries Ltd. filed a patent lawsuit against Indian generic manufacturers—Lupin Ltd. and Aurobindo Pharma Ltd—to prevent them from releasing generic version of Austedo in the market.
Reasons to subscribe to Asia Pacific huntingtons disease treatment market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Asia Pacific huntingtons disease treatment market databook
-
Our clientele includes a mix of huntingtons disease treatment market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific huntingtons disease treatment market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific huntingtons disease treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Asia Pacific huntingtons disease treatment market size, by country, 2018-2030 (US$M)
Asia Pacific Huntingtons Disease Treatment Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
